China’s Minister of Commerce, Wang Wentao, convened a high-level meeting with top executives from the global pharmaceutical industry, including leaders from Bristol-Myers Squibb, GlaxoSmithKline, Danaher, Pfizer, Abbott, Sanofi, Takeda Pharmaceuticals, Gilead, Merck, Sharp & Dohme, and more. Also in attendance was a representative from the Pharmaceutical Research and Manufacturers of America (PhRMA). The gathering aimed to discuss strategies for fostering global innovation cooperation within the pharmaceutical sector and to address the development of foreign-funded pharmaceutical enterprises in China.
During the meeting, Wang Wentao emphasized that innovation in the pharmaceutical industry is inherently dependent on global collaboration. He noted that the business community widely rejects the broad application of national security concepts and is against any form of decoupling or disconnection from China. The participating executives conveyed their optimism regarding China’s economic growth and the favorable business climate, which has reinforced their commitment to invest further in the country. They also acknowledged the series of policies recently introduced by China to attract foreign investment, which they believe will address the concerns and suggestions of pharmaceutical companies and significantly boost the innovative development of the industry.- Flcube.com
